NCT02713789View on ClinicalTrials.gov

Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 24, 2017

Study Completion Date

August 24, 2017

Conditions
Erectile Dysfunction
Interventions
DRUG

hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)

DRUG

Placebo (PBS-20% sucrose)

Trial Locations (1)

1180

Dasman Diabetes Institute, Kuwait City

Sponsors

Collaborators (1)

Ion Channel Innovations
All Listed Sponsors
collaborator

Dasman Diabetes Institute

OTHER

collaborator

Ion Channel Innovations

INDUSTRY

lead

Urovant Sciences GmbH

INDUSTRY